| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/31/2001 | EP1071794A1 A method for inhibiting tumor invasion or spreading in a subject |
| 01/31/2001 | EP1071787A1 Tao protein kinases and methods of use |
| 01/31/2001 | EP1071784A1 Polypeptides from moraxella (branhamella) catarrhalis |
| 01/31/2001 | EP1071783A2 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071780A1 Soluble protein ztmpo-1 |
| 01/31/2001 | EP1071772A2 Fizz proteins |
| 01/31/2001 | EP1071763A1 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates |
| 01/31/2001 | EP1071758A1 Porcine adenovirus type 3 genome |
| 01/31/2001 | EP1071752A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| 01/31/2001 | EP1071749A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 01/31/2001 | EP1071715A2 TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA) |
| 01/31/2001 | EP1071712A1 Sp22, a fertility-associated protein from sperm and a method for evaluating and affecting male fertility using it |
| 01/31/2001 | EP1071709A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 01/31/2001 | EP1071700A1 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/31/2001 | EP1071698A1 Nucleic acid sequences and proteins associated with aging |
| 01/31/2001 | EP1071694A1 Staphylococcus aureus spo0j2: polynucleotide and protein |
| 01/31/2001 | EP1071470A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 01/31/2001 | EP1071469A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071460A1 INTERNALIZING ErbB2 ANTIBODIES |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071458A1 Humanized antibody and uses thereof |
| 01/31/2001 | EP1071457A1 Polymer particle vaccine delivery system |
| 01/31/2001 | EP1071456A1 Vaccines with an ltb adjuvant |
| 01/31/2001 | EP1071453A2 Live vaccines and methods of treatment therewith |
| 01/31/2001 | EP1071452A1 Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof |
| 01/31/2001 | EP1071451A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/31/2001 | EP1071450A2 Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy |
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071443A1 Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof |
| 01/31/2001 | EP1071438A2 Stabilised virus preparation |
| 01/31/2001 | EP1071436A1 Immune effector cell hybrids |
| 01/31/2001 | EP1071412A2 Identification of bacterial avirulence genes and their products; vaccines and pharmaceutical compositions containing them |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071407A1 Lipophilic microparticles containing a protein drug or antigen and formulation comprising same |
| 01/31/2001 | EP1071400A1 Drug delivery of proteins from polymeric blends |
| 01/31/2001 | EP1071377A1 Needleless administration of polynucleotide formulations |
| 01/31/2001 | EP1071333A1 Induction of immunity against tumor self-antigens |
| 01/31/2001 | EP1071327A1 Autoantigenic fragments, methods and assays |
| 01/31/2001 | EP1071325A1 Compositions and methods for antigen-specific vaccination |
| 01/31/2001 | EP0598818B1 Escherichia coli o-polysaccharide-protein conjugate vaccine |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282251A Method and material for treating and preventing mucosal tissue inflammation |
| 01/31/2001 | CN1282218A Compositions and method for treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/31/2001 | CN1281863A Recombinant Newcastle disease virus capable of being used as embryo vaccine |
| 01/31/2001 | CN1281732A Imnunoglobulin injection for sheep and rabbit |
| 01/31/2001 | CN1281731A Immunoglobulin injection for pig |
| 01/31/2001 | CN1281730A Immunoglobulin injection for poultry |
| 01/31/2001 | CN1281729A Immunoglobulin injection for dog and cat |
| 01/31/2001 | CN1281728A Immunoglobulin injection for pigeon |
| 01/30/2001 | US6180771 Given nucleotide sequence; useful for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites |
| 01/30/2001 | US6180614 Methods of immunization of aquaculture species by introducing dna expression systems into the aquaculture species |
| 01/30/2001 | US6180398 Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
| 01/30/2001 | US6180387 Nucleotide sequence coding an enzymatic polypeptide; for the detection of bactericides and batericidal agonist and antagonists which prevent bacterial infection |
| 01/30/2001 | US6180384 Compounds |
| 01/30/2001 | US6180383 Insect proteolytic enzyme; for the prevention of insect infestation |
| 01/30/2001 | US6180380 Cloning of a new member of the serine threonine kinase family |
| 01/30/2001 | US6180377 Humanized antibodies |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | US6180369 Varicella-zoster virus antigen |
| 01/30/2001 | US6180355 Method for diagnosing and treating chronic pelvic pain syndrome |
| 01/30/2001 | US6180140 Modified amino acids for drug delivery |
| 01/30/2001 | US6180112 Pasteurella haemolytica vaccine |
| 01/30/2001 | US6180111 Vaccine delivery system |
| 01/30/2001 | US6180110 Attenuated hepatitis a virus vaccine which grows in MRC-5 cells |
| 01/30/2001 | US6180109 Nucleotide and polypeptide sequences of pestivirus strains |
| 01/30/2001 | US6180106 For treating hypersensitivity reaction in mammals; as antitussive agent, antiallergen, antihistmine, to suppress itching and as antiinflammatory agent |
| 01/30/2001 | US6180104 Can be used such as nucleotide probes, combining with foreign dna sequences to produce novel t-cell receptors, which can be used in an analogous manner as antibodies, or constructs can be provided which provide for extrachromosomal elements |
| 01/30/2001 | US6180099 Method of using immunoglobulin and fiber-containing compositions for human health |
| 01/30/2001 | US6180097 For treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic by using superantigens, including staphyloccocal enterotoxins b and c, to stimulate tumor draining lymph node cells |
| 01/30/2001 | CA2272317C Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 01/29/2001 | CA2279134A1 Novel strategy for carbohydrate-based therapeutic vaccines |
| 01/27/2001 | CA2312626A1 A recombinant newcastle disease virus as an embryo vaccine |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001005988A1 Live recombinant vaccine against avian leukosis virus using a marek's disease virus (mdv) virus as vector |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005978A1 FimH ADHESIN-BASED VACCINES |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005967A1 Splice variants of cd40-receptor |
| 01/25/2001 | WO2001005934A2 Feline calicivirus genes and vaccines, in particular recombined vaccines |
| 01/25/2001 | WO2001005835A1 Inactivated vaccine against feline calicivirus disease |
| 01/25/2001 | WO2001005827A1 Fima PILUS-BASED VACCINES |
| 01/25/2001 | WO2001005823A2 Tryptase inhibitor |
| 01/25/2001 | WO2001005820A2 Method for down-regulating gdf-8 activity |
| 01/25/2001 | WO2001005427A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | WO2001005425A2 Combined preparations comprising daunorubicin derivatives and her2 antibodies |
| 01/25/2001 | WO2001005424A2 Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis |
| 01/25/2001 | WO2001005418A2 Tissue regenerating agent |
| 01/25/2001 | WO2001005410A1 Neurotropic virus transport |
| 01/25/2001 | WO2000068240A8 NOVEL aroA |
| 01/25/2001 | WO2000062817A3 Inducible vaccines |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000057908A3 Attenuated dengue-1 virus vaccine |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |